Medication Use for Hypercholesterolemia in the Pediatric Population

Thomas L. Lenz, Jessica C. Larson

Research output: Contribution to journalArticle

Abstract

The past few decades have shown an increase in the prevalence of chronic conditions in the pediatric population. One of the chronic conditions that appears to be on the rise in this population is hypercholesterolemia. At the same time, the rate of obesity is increasing in children and adolescents and may be putting our youth at risk for abnormal lipid levels. First-line prevention and treatment should involve intensive lifestyle medicine therapy. If warranted, however, the use of medications may be started as early as 8 years of age, but this has many unknown variables related to safety and efficacy. Caution and vigilant observation for drug interactions and adverse events is warranted by the health care team and family members throughout treatment with drug therapy.

Original languageEnglish
Pages (from-to)455-457
Number of pages3
JournalAmerican Journal of Lifestyle Medicine
Volume6
Issue number6
DOIs
StatePublished - Nov 2012

Fingerprint

Hypercholesterolemia
Pediatrics
Population
Patient Care Team
Drug Interactions
Life Style
Therapeutics
Obesity
Observation
Medicine
Lipids
Safety
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Medication Use for Hypercholesterolemia in the Pediatric Population. / Lenz, Thomas L.; Larson, Jessica C.

In: American Journal of Lifestyle Medicine, Vol. 6, No. 6, 11.2012, p. 455-457.

Research output: Contribution to journalArticle

@article{c7111baafcb04744bc954676cf0d6b4b,
title = "Medication Use for Hypercholesterolemia in the Pediatric Population",
abstract = "The past few decades have shown an increase in the prevalence of chronic conditions in the pediatric population. One of the chronic conditions that appears to be on the rise in this population is hypercholesterolemia. At the same time, the rate of obesity is increasing in children and adolescents and may be putting our youth at risk for abnormal lipid levels. First-line prevention and treatment should involve intensive lifestyle medicine therapy. If warranted, however, the use of medications may be started as early as 8 years of age, but this has many unknown variables related to safety and efficacy. Caution and vigilant observation for drug interactions and adverse events is warranted by the health care team and family members throughout treatment with drug therapy.",
author = "Lenz, {Thomas L.} and Larson, {Jessica C.}",
year = "2012",
month = "11",
doi = "10.1177/1559827612455625",
language = "English",
volume = "6",
pages = "455--457",
journal = "American Journal of Lifestyle Medicine",
issn = "1559-8276",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Medication Use for Hypercholesterolemia in the Pediatric Population

AU - Lenz, Thomas L.

AU - Larson, Jessica C.

PY - 2012/11

Y1 - 2012/11

N2 - The past few decades have shown an increase in the prevalence of chronic conditions in the pediatric population. One of the chronic conditions that appears to be on the rise in this population is hypercholesterolemia. At the same time, the rate of obesity is increasing in children and adolescents and may be putting our youth at risk for abnormal lipid levels. First-line prevention and treatment should involve intensive lifestyle medicine therapy. If warranted, however, the use of medications may be started as early as 8 years of age, but this has many unknown variables related to safety and efficacy. Caution and vigilant observation for drug interactions and adverse events is warranted by the health care team and family members throughout treatment with drug therapy.

AB - The past few decades have shown an increase in the prevalence of chronic conditions in the pediatric population. One of the chronic conditions that appears to be on the rise in this population is hypercholesterolemia. At the same time, the rate of obesity is increasing in children and adolescents and may be putting our youth at risk for abnormal lipid levels. First-line prevention and treatment should involve intensive lifestyle medicine therapy. If warranted, however, the use of medications may be started as early as 8 years of age, but this has many unknown variables related to safety and efficacy. Caution and vigilant observation for drug interactions and adverse events is warranted by the health care team and family members throughout treatment with drug therapy.

UR - http://www.scopus.com/inward/record.url?scp=84867735459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867735459&partnerID=8YFLogxK

U2 - 10.1177/1559827612455625

DO - 10.1177/1559827612455625

M3 - Article

VL - 6

SP - 455

EP - 457

JO - American Journal of Lifestyle Medicine

JF - American Journal of Lifestyle Medicine

SN - 1559-8276

IS - 6

ER -